82626-01-5CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12JRTIDHTUMYMPRU-UHFFFAOYSA-NAlpidem is a member of imidazoles.
82626-01-5DTXSID8049046CHEMBL54349CHEBI:135649White to Off-White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Alpidem
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
개요Alpidem is an imidazopyridine antianxiety agent with anticonvulsant properties. It is claimed to be the first non-benzodiazepine anxiolytic to show selectivity for the omega-1 modulatory site of the GABA, receptors. Alpidem is reported to be superior to buspirone and similar to the benzodiazepines, but is significantly better tolerated with lower abuse potential.
용도A peripheral benzodiazepine GABAA receptor ligand, a new anxiolytic